Last reviewed · How we verify
NCT06913244
Long-Term Multidisciplinary Physiotherapy for Breast Cancer Survivors: A Randomized Controlled Trial
NA trial testing Multidisciplinary Physiotherapy Program (MD Physio) in Breast Cancer in 146 participants. Currently enrolling.
1 January 2027
Quick facts
| Lead sponsor | Al Hayah University In Cairo |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 146 |
| Start date | 23 April 2025 |
| Primary completion | 1 January 2027 |
| Estimated completion | 1 January 2027 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Multidisciplinary Physiotherapy Program (MD Physio)
- Standard Physiotherapy Care
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
- Breast Cancer Female — all drugs for Breast Cancer Female →
Sponsor
Al Hayah University In Cairo
Who can join
Adults 18 to 65, any sex, with Breast Cancer or Breast Cancer Female. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This multi-center randomized controlled trial (RCT) evaluates the long-term (12-month) effectiveness of a standardized multidisciplinary physiotherapy program versus standard care on persistent pain, upper limb (UL) dysfunction, and cancer-related fatigue (CRF) in breast cancer survivors. The study also examines improvements in quality of life and psychological well-being. The standardized intervention combines specific exercise therapy, manual therapy, education, and mind-body interventions and is designed to produce sustained benefits beyond the acute rehabilitation phase.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06913244
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Al Hayah University In Cairo trials
Trials by the same sponsor.
- NCT07513779 — Residual Eccentric Strength Deficits and Deep Scar Tissue Thickness in Patients With Tennis Leg · recruiting
- NCT07166328 — Frontal/Axial and Self Body Image In Scoliosis · recruiting
- NCT06916650 — Comparing HILT, Steroid Injection, and Manual Therapy for Frozen Shoulder · NA · recruiting
- NCT06916676 — HILT Dose Optimization for Knee Osteoarthritis Pain · NA · recruiting
- NCT06916663 — RCT Comparing Upper Body vs. Combined Exercise Protocols During Active Diabetic Foot Ulcer Treatment · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06913244 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Al Hayah University In Cairo
- Last refreshed: 6 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06913244.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing